Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL117946 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL29349956 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL29384797 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL31714182 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL29358863 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL119588 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL31369598 | 0.97 | MDM2 (0.53) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL30516252 | 0.95 | PTPN1 (0.54) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL30516240 | 0.95 | PTPN1 (0.54) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL30516235 | 0.95 | PTPN1 (0.54) | MDM4TP53MDM2PTPN1ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116751139-A | Preparation method of N- (9-fluorenylmethoxycarbonyl) -O-tert-butyl-L-tyrosine | 山西诺成制药有限公司 | 2023-09-15 | — | — | CN | claimed |
| EP-4748847-A1 | PEPTIDE COMPLEX HAVING VEGFR -2 AGONIST ACTIVITY | Peptidream Inc (JP) | 2026-05-27 | — | — | EP | disclosed |
| CN-120192365-A | Colipase inhibiting peptide and application thereof | 宜客美股份有限公司 | 2025-06-24 | — | — | CN | disclosed |
| US-20250171494-A1 | METHOD FOR SYNTHESIZING PEPTIDE CONTAINING N-SUBSTITUTED AMINO ACID | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-05-29 | — | — | US | disclosed |
| US-12297293-B2 | Peptide compounds targeting PD-1 receptor as well as preparation and applications thereof | NANTONG UNIVERSITY (CN) | 2025-05-13 | — | — | US | disclosed |
| US-12281141-B2 | Method for synthesizing peptide containing N-substituted amino acid | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-04-22 | — | — | US | disclosed |
| CN-119264216-B | Preparation method of tyrosine serine pseudo dipeptide | 成都普康唯新生物科技有限公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-119684180-A | Method for synthesizing thio-ester compound | 南通大学 | 2025-03-25 | — | — | CN | disclosed |
| CN-119684260-A | Ferritin ligand, ferritin degradation agent, pharmaceutical preparation and application | 贵州大学 | 2025-03-25 | — | — | CN | disclosed |
| WO-2025043696-A1 | ANTIVIRAL POLYPEPTIDE ANALOGUE | 上海多米瑞生物技术有限公司 | 2025-03-06 | — | — | WO | disclosed |
| EP-1549668-A1 | TUMOR TARGETING AGENTS AND USES THEREOF | Karyon OY (FI) | 2005-07-06 | — | — | EP | disclosed |
| EP-1499313-A2 | HETEROCYCLIC DERIVATIVES AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-26 | — | — | EP | disclosed |
| WO-2004031221-A9 | TUMOR TARGETING AGENTS AND USES THEREOF | KARYON OY (FI) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004031221-A1 | TUMOR TARGETING AGENTS AND USES THEREOF | KARYON OY (FI) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004031218-A1 | TUMOR TARGETING AGENTS AND USES THEREOF | KARYON OY (FI) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004031219-A1 | TUMOR TARGETING AGENTS AND USES THEREOF | KARYON OY (FI) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004031220-A1 | TUMOR TARGETING AGENTS AND USES THEREOF | KARYON OY (FI) | 2004-04-15 | — | — | WO | disclosed |
| US-20040010014-A1 | Novel compounds as opioid receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2004-01-15 | — | — | US | disclosed |
| WO-2003092688-A2 | HETEROCYCLIC DERIVATIVES AS OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-11-13 | — | — | WO | disclosed |
| US-6359061-B1 | COMBINATORIAL LIBRARIES ARE USEFUL FOR SCREENING IN BIOLOGCAL ASSAYS IN ORDER TO IDENTIFY PHARMACEUTICALLY USEFUL COMPOUNDS | ISIS PHARMACEUTICALS, INC. | 2002-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171494-A1 | METHOD FOR SYNTHESIZING PEPTIDE CONTAINING N-SUBSTITUTED AMINO ACID | NPPA, VIP, DNPEP | MDM4 4142/4885TP53 2781/4885MDM2 3845/4885 |
| US-12281141-B2 | Method for synthesizing peptide containing N-substituted amino acid | NPPA, VIP, DNPEP | MDM4 4142/4885TP53 2781/4885MDM2 3845/4885 |
| US-20040010014-A1 | Novel compounds as opioid receptor modulators | OPRL1, OPRK1, OPRM1 | MDM4 4706/4885TP53 4868/4885MDM2 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.